IDEXX Laboratories Inc

Idexx reported second-quarter results that featured organic revenue and earnings growth of 9% and 15%, respectively. Management raised its full-year outlook, and shares rose 4% on Aug. 4.

Why it matters: While there are signs that consumers are under some financial strain thanks to fuel and food prices, demand for pet diagnostics has remained solid. Idexx's placement of analyzers, sales of consumables, and reference lab services have delivered strong growth On one hand, we've seen that visits to the vet have been in negative territory for the last three years, driven by wellness visits. On the other hand, nonwellness visits that may involve an acute or symptomatic pet have held up respectably. We think the aging of the pandemic-pet boom should also shore up this trend.

The bottom line: Given that our 2026 estimates remain within management's upgraded outlook, we're leaving our $470 fair value estimate unchanged. We remain confident in Idexx's wide economic moat and the intangible assets and switching costs that support it. The ongoing expansion of Idexx's installed base of benchtop analyzers paves the way for a stream of consumable revenue.

Big picture: Idexx is in the midst of a strong waxing innovation cycle, in our view. The impressive adoption of the InVue analyzer and the ear cytology and blood morphology assays offer truly novel options that address common health issues. Considering adoption cycles of new testing platforms can stretch out over years, this bodes well for the InVue analyzer, which Idexx started shipping to practices about 18 months ago. As it has done with past platforms, Idexx is making good on plans to capitalize on InVue by rolling out more new tests and panel options, starting with oncology.

While Idexx has already introduced a test for canine lymphoma, it will soon expand the oncology panel to include mast cell tumor detection. Considering cancer affects an estimated half of dogs eventually, this panel will provide early diagnosis for two of the most common canine cancers. Both of these conditions have seen substantial progress in treatment, especially when detected at an early stage. For canine lymphoma, chemo treatment can often put the disease into remission. With mast cell tumors found early, localized surgical removal can often let the dog live to normal life expectancy for its breed. We think this new oncology panel will be very appealing to both vets and pet owners who are concerned about aging dogs.

We're holding steady on our fair value estimate of $470 per share, which reflects the robust launch of the Invue analyzer as well as solid mid-single-digit growth in the reference labs.

We expect Idexx to benefit from higher long-term demand for pet diagnostics, as the pandemic-driven surge in pet adoption has led to increased pet ownership penetration, particularly among puppies and kittens adopted since 2020. We estimate average annual revenue growth of 8% through 2030. We remain most bullish about VetLab consumables and the reference lab segments—the two largest product lines in the companion animal segment. Despite the slowdown in instrument placement during the pandemic, Idexx has resumed its aggressive placement of analyzer units, helped by the new Invue platform, which should lead to VetLab consumable revenue growth that averages in the low double digits through 2030. Considering the opportunities for cross-selling and Idexx's ongoing progress in penetrating new animal hospitals with its analyzer instruments, we believe there is plenty of potential for the sales consultants to sell new services and develop stickier relationships.

We think Idexx has dug a wide economic moat that rests on the firm’s intangible assets that have complemented switching costs in supporting highly attractive economic profits over the last two decades.

Idexx is the leader in point-of-care diagnostic tests and in-house analyzer equipment, and holds a well-established position in the reference lab duopoly with VCA (now part of privately held Mars). Idexx's economic moat is driven by several sources.

First, Idexx benefits from a layer of switching costs across a number of its products. For example, with Idexx's practice and information management software, once the animal hospital staff has invested the time to enter all the patient and client information and become familiar with the software, the inconvenience of installing and learning a whole new system means customers tend to stick with Idexx. The same principle applies to its in-house test equipment. Once the practice has installed the base equipment and trained its vet techs on it, practices are more likely to stick with Idexx than to switch to another brand, which leads to a continuing stream of high-margin revenue from proprietary assays.

Customer switching costs also rise further if the vet practice purchases multiple Idexx products and services. For example, the integration of Idexx reference lab data and Idexx in-house analyzer data with Idexx practice management software makes the workflow smoother, and simplifies the transmission of test data and patient medical records. This leaves customers more reluctant to switch to another vendor. These switching costs have driven retention rates for analyzer consumables, the reference lab, and the highest-volume rapid assay test to 99.5%, 97.6%, and 97%, respectively.

Second, the firm also relies on intangible assets, including technical know-how and some intellectual property in its diagnostic tests. Idexx's key competitive advantage is its ability to consistently innovate in diagnostic tests. The firm has come up with new generations of assays and laboratory equipment that can test for more diseases and apply emerging diagnostic technology previously invented for humans to production animals and water testing, as well as companion animals. Idexx's products and services typically focus on testing for new types of diseases and parasites, improving turnaround time on test results, increasing the accuracy of results, and enhancing the convenience of on-site testing. As a result, Idexx and its rivals compete on the basis of product features rather than price. The latest in Idexx's lineup of diagnostics is the Invue analyzer that handles blood morphology and cytology tests.

Beyond these technology-based intangibles, Idexx’s major secret weapon lies in its sales representatives and field organization that provide high-touch service to animal hospitals. Idexx reps have proven themselves successful in providing counsel on optimizing hospital operations and improving the profit profile for vets. We have yet to see any other animal health firms carve out this sort of integrated role in animal hospital operations. We think Idexx’s commercial organization, level of service, and its strong relationships with vets is why Idexx was able to switch to direct distribution of its rapid test kits and analyzer consumables in 2015—despite holding a near-monopoly position with the three largest animal health distributors—without a hint of competitive pressure.

Finally, we think Idexx’s reference lab also enjoys elements of cost advantage over most other diagnostic labs because of its extensive scale. Though this aspect of Idexx is limited to its reference lab and doesn’t seem substantial enough for us to consider this as another source of moat for the entire enterprise, it bears noting, from our perspective. With a large, national lab network, Idexx is able to run these tests at lower costs thanks to higher throughput. Volume, route density, and ensuing efficient use of the labs result in more attractive margins than smaller-scale independent labs can offer.

Unlike human healthcare, pet health services and products require cash payments—thereby bypassing the reimbursement issues and pricing pressure associated with third-party payers.

Anecdotal information from vets suggests that Idexx's well-integrated and user-friendly practice management software helps hospitals switch to and stick with Idexx's products and services.

Idexx's sales and customer support staff garner high marks for providing high-touch service to vet practices.

International sales account for a substantial chunk of Idexx's total revenue; as the US dollar strengthens, Idexx would feel the pain on its top and bottom lines.

Idexx's rapid assay product line is most vulnerable to competitive pressure through the vet distributors. The firm could see growth in this area stagnate or decline.

Shares typically trade at a high multiple to forward earnings, so even a small pullback in pet healthcare spending could result in a material drop in share price.